Nature of change: Re-appointment of Ms. Akshita Ostwal (DIN: 10026552) as an Independent Director of the Company for a second term.
Effective date and tenure: The re-appointment is effective from September 05, 2026, for a term of five consecutive years ending on September 04, 2031 (both days inclusive).
Approval mechanism: The reappointment was approved by the Members of the Company at the 83rd Annual General Meeting held on August 24, 2026.
Brief profile and qualifications: Ms. Akshita Ostwal is the founder of Akshita Surana & Associates, a peer-reviewed firm of practicing company secretaries. She has over ten years of experience in corporate laws and IPR laws advisory, consulting, and litigation. She is a fellow practicing company secretary, a registered trademark agent, and holds a Master's degree in Law. Additionally, she is a member of the Chartered Governance Institute of UK & Ireland.
Eligibility confirmation: The company confirmed that to the best of their knowledge and information, and as confirmed by Ms. Akshita Ostwal, she has not been debarred from holding the office of Director by virtue of an order of SEBI or any other authority.
Relationship with other directors: Not applicable as disclosed in the annexure.
Any Other Material Information
Regulatory compliance: The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular dated 30th January, 2026.
Additional verification: Information as required under Circular No. NSE/CML/2018/02 dated June 20, 2018 issued by NSE confirms that Ms. Akshita Ostwal is not debarred from holding office of a Director.
Availability of information: The information is also available on the Company's website at www.balaxipharma.in.
